US6701002056
US6701002056
Novo Nordisk A/S
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 170.57B EUR | 212.13B EUR | 163.08B EUR | 226.08B EUR |
Enterprise Value | 264.21B EUR | 307.77B EUR | 288.34B EUR | 330.58B EUR |
Valuation Multiples | ||||
Trailing P/E | 9.45x | 1.82x | 1.34x | 3.08x |
Forward P/E | 11.62x | -- | -- | -- |
Price to Sales | 0.52x | 0.64x | 0.5x | 0.98x |
Price to Book | 5.15x | 0.96x | 0.8x | 1.17x |
EV/Revenue | 0.8x | 0.93x | 0.88x | 1.43x |
EV/EBITDA | 1.52x | 1.91x | 1.64x | 3.1x |
Price to FCF (P/FCF) | 4.53x | 4.44x | 5.28x | 12x |
EV/FCF | 7.01x | 6.44x | 9.33x | 17.54x |
FCF Yield | 22.09% | 22.53% | 18.94% | 8.34% |